The randomised phase II trial EMERGE demonstrated no significant differences in ORR as compare to standard chemotherapy (6 vs. 7%), but the activity of GV appeared to be increased in TNBC and especially in case of gpNMB-overexpression (≥25% epithelial cancer cells staining positive by IHC) (Yardley et al., 2015). The gene discussed is GPNMB; the disease is cancer.